FCGR2A and neoplasm: The selective depletion of immunosuppressive Tregs aligns with preclinical studies demonstrating that OX40 agonists can deplete intratumoral Tregs via FcγR-mediated mechanisms, thereby enhancing anti-tumor immunity (33).